Log In

Forgot Password?
Create New Account

Loading... please wait

2021 Annual Meeting | C39 - Multiple Sclerosis Therapy: Disease-modifying Treatment

Monday 04/19/21
08:00 AM - 09:00 AM EDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Jacqueline Bernard, MD, FAAN
Nancy J. Newman, MD, FAAN
Multiple Sclerosis
Participants should be comfortable with selecting DMTs based on risk stratification, including pregnancy and family planning for RRMS, SPMS, and PPMS; understand complications associated with approved DMTs in RRMS, SPMS, and PPMS; feel comfortable creating an algorithm for patients who break through therapies and no longer meet "NEDA" criteria; and provide updates on the impact of COVID-19 disease and vaccination on DMT doses.
1.00 CME credit
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Introductory
Advanced Practice Provider
Fellow, Resident, General Neurologist, Advanced Practice Provider
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
08:00 AM - 08:50 AM EDT Speaker MS Therapy: Disease-modifying Treatment
Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD
08:50 AM - 09:00 AM EDT Q&A Live Q&A
Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD
Faculty Disclosures
Jacqueline Bernard, MD, FAAN Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care.
Michael A. Lane, MD Dr. Lane has nothing to disclose.
Nancy J. Newman, MD, FAAN Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurophoenix. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurophth. The institution of Dr. Newman has received research support from GenSight. The institution of Dr. Newman has received research support from Chiesi/Santhera. The institution of Dr. Newman has received research support from NINDS/NIH. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.